Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cervarix Gets One Up On Gardasil In Cross-Protection: HPV-31 In FDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

More limited cross protection claim approved by FDA still gives GSK a selling point in its effort to dislodge Merck's Gardasil from its exclusive position in the U.S. HPV protection vaccine market.

You may also be interested in...



Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA

Industry is calling on FDA to write separate rules for assessing adjuvants. This would encourage innovation in immunotherapies, the Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America contend.

Adjuvants Need Approval Pathway Separate From Vaccines, Industry Tells FDA

Industry is calling on FDA to write separate rules for assessing adjuvants. This would encourage innovation in immunotherapies, the Biotechnology Industry Organization and Pharmaceutical Research and Manufacturers of America contend.

Gardasil Anal Cancer Indication To Face FDA Advisory Committee Scrutiny

Supplemental application filed earlier this year is part of Merck's strategy to broaden use of the HPV vaccine, although its bid to expand the label to women ages 27-45 has thus far been blocked by the agency.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS068606

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel